Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Buparlisib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 27 May 2019 Planned End Date changed from 1 Jun 2019 to 1 Aug 2019.
- 14 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.
- 13 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History